CMO Gallus taps Xcellerex for single-use capacity

Fledgling contract manufacturer Gallus Biopharmaceuticals sees something it likes in Xcellerex single-use technology--quick capacity expansion. The two companies agreed this week to a multi-piece deal that will equip Gallus with not just the means for quick manufacturing capacity expansion, but also single-use gear for drug development work.

Gallus had acquired J&J Centocor's FDA-approved, commercially certified biologics manufacturing plant in St. Louis, which makes Remicade and Stelara. The CMO is expanding the facility for capacity, the addition of a clinical services suite and the expansion of an existing development lab. The Xcellerex deal marks Gallus's first equipment purchase.

The company says it will invest $20 million on the facility. It plans to eventually add 160 employees to the 160 already employed there. The average salary at Gallus is reportedly $88,500.

Gallus apparently walked into the Xcellerex showroom presold on the FlexFactory platform and components. In addition to single-use XDR bioreactors for commercial manufacturing capacity expansion, the CMO ordered small-scale (10-liter) bioreactors for its development lab. It also ordered a turnkey FlexFactory cGMP manufacturing line with XDR single-use bioreactors to 2,000 liters for clinical trial supply production.

- see the Gallus release
- here's the story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.